In this excerpt from "The Science Behind the Coronavirus series IV," Los Angeles Times executive chairman Dr. Patrick Soon-Shiong discusses the threat that "vaccine nationalism" poses to low- and middle-income countries. Dr. Soon-Shiong's guest is the Johannesburg-based virologist Shabir Madhi, who managed South Africa's trials of the AstraZeneca-Oxford vaccine.
You can watch the full "Science Behind the Coronavirus" series at www.latimes.com/secondopinion.
Patrick Soon-Shiong is a surgeon and scientist who has spent his career studying the human immune system to fight cancer and infectious disease. Last year, Soon-Shiong's company, ImmunityBio, received permission from the Food and Drug Administration to begin Phase 1 trials of its COVID-19 vaccine candidate. The company has also received approval to begin trials in South Africa, where a new variant of the virus has led to a sudden rise in cases.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
You can watch the full "Science Behind the Coronavirus" series at www.latimes.com/secondopinion.
Patrick Soon-Shiong is a surgeon and scientist who has spent his career studying the human immune system to fight cancer and infectious disease. Last year, Soon-Shiong's company, ImmunityBio, received permission from the Food and Drug Administration to begin Phase 1 trials of its COVID-19 vaccine candidate. The company has also received approval to begin trials in South Africa, where a new variant of the virus has led to a sudden rise in cases.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
- Category
- U.S. & Canada
- Tags
- Los Angeles Times, LA Times, L. A. Times
Sign in or sign up to post comments.
Be the first to comment